Amber Therapeutics
amber-tx.com
Actively hiring
Neurotech & Neuromodulation
Health Care
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$100M
1 round on record
Latest round
$100M
Series A · Jun 2024 · 2 yr ago
Backers
3
F-Prime Capital, Lightstone Ventures
The money's age
Long since its last round
27 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series A | Jun 2024 | $100M | — | streetinsider.com |
Backed byfrom the funds' portfolios and accelerator catalogs
F-Prime Capital 
Lightstone Ventures 
Oxford Science Enterprises Similar startupsby what they do, their industry and backers
Cala TAPS™ Therapy is now covered by Medicare for qualifying beneficiaries! Read about it now We're building innovative therapies that…
Decoding neural signals to restore lives. The nervous system is the body’s operating system.
Neuromodulation technology that enhances your sensory acuity improving clarity of hearing, vision, and touch.
NeuroHarmonics is developing non-invasive deep-brain neuromodulation with focused ultrasound — precise, reversible access to the deep…
Paradromics develops a high bandwidth brain-computer interface intended to restore communication for people with severe paralysis. Founded…
Neurosom™ is a company established to develop medical devices and therapeutic protocols for improving sleep through both psychological…
News
Amber Therapeutics strengthens its Board and Leadership team, opens UK headquarters and expands EU feasibility study for mixed urinary incontinence, increasing momentum towards a pivotal trial in the US
Oxford, UK - 24 February 2026 - Amber Therapeutics today announced a series of updates to its business highlighting the significant progress it has made...
Read more
Report
Amber Therapeutics Closes $100 Million Series A Financing to Advance Breakthrough Amber-UI Neuromodulation Therapy for Mixed Urinary Incontinence towards US FDA Approval
US approval would make Amber-UI the first fully implantable adaptive neuromodulation therapy for women with mixed urinary incontinence (MUI)By targeting the pudendal nerve, Amber-UI has the unique potential to treat the millions of women who suffer from b
Read more
Report
Amber Therapeutics Closes $100 Million Series A Financing to Advance Breakthrough Amber-UI Neuromodulation Therapy for Mixed Urinary Incontinence towards US FDA Approval
US approval would make Amber-UI the first fully implantable adaptive neuromodulation therapy for women with mixed urinary incontinence (MUI)By targeting...
Read more
Report
Amber Therapeutics Closes $100 Million Series A Financing to Advance Breakthrough Amber-UI Neuromodulation Therapy for Mixed Urinary Incontinence towards US FDA Approval
Read more
Report
Amber Therapeutics announces positive preliminary results from its first-in-human investigation of Amber-UI, its new adaptive implanted pudendal neuromodulation system for urinary incontinence
Key initial results from AURA-2 study highlight good safety and scalability of Amber-UI therapy A strong efficacy signal was seen in the form of complete...
Read more
Report
Pro access
Upgrade to see all 6 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.
Financials
Total raised
$100M
Latest round
Series A
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Series A | 2024 | $100M | Details |